Tina Papagiannopoulos

Washington, DC

I counsel FDA-regulated clients in regulatory, enforcement and policy matters that have the potential to materially impact their business.

Tina Papagiannopoulos assists clients with a variety of regulatory, policy, and compliance matters related to the U.S. Food & Drug Administration (FDA) and the Federal Trade Commission (FTC), with a primary focus on therapeutics. She advises clients about product development and regulatory approval, marketing exclusivities, advertising and promotion, post-approval obligations, and responding to enforcement actions and investigations. She counsels clients on effective engagement with the FDA through formal agency meetings as well as through public comment and petitioning processes. She also provides subject-matter expertise on various litigation and transaction matters involving life sciences companies.


  • Georgetown University Law School, LL.M.
  • University of Virginia School of Law, J.D.
  • Georgetown University School of Business, B.S.B.A.

Bar and Court Admissions


  • District of Columbia
  • Maryland


  • “Federal Trade Commission v. Martin Shkreli” chapter in FDLI’s Top Food and Drug Cases 2021 & Cases to Watch 2022

Foley Hoag Publications

Publication 08/05/2021

Honors & Involvement


  • The Best Lawyers in America: Ones to Watch
  • Editorial Advisory Board, Food and Drug Law Journal, Food and Drug Law Institute

Speaking Engagements

  • A Hatch-Waxman Review: What to Know About the Hatch-Waxman Act As It Turns 39+, Foley Hoag Webinar (October 2022)
  • “Transforming Digital Health: How Providers and DTx Companies Can Utilize RPM and RTM Codes to Improve Care,” Foley Hoag Webinar (December 2021)
  • "Digital Therapeutics Seminar Series - Part I," Foley Hoag Webinar (June 2021)
  • "The Maturation of the CBD Market: from New York, FDA and Beyond," Foley Hoag Webinar (August 26, 2021)
  • “COVID Resilient Environment and Clinical Trials,” NC Biosciences Organization (November 2020)